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A B S T R A C T
Background: Cardiac troponin is widely accepted as a biomarker of myocyte injury in patients with
myocardial ischemia. Patients with congestive heart failure are also associated with elevated cardiac
troponin and it is a very sensitive prognostic marker. However, the mechanisms of troponin elevation in
patients with heart failure are not fully understood. Decompensated state itself is suggested as a factor
contributing to elevated cardiac troponin-T. However comparison between invasive hemodynamic
parameters and cardiac troponin-T is insufﬁcient.
Methods: Data were collected from 167 patients in stable, chronic HF, without acute coronary syndrome,
recent revascularization, mitral stenoses, hemodialysis, or clinically signiﬁcant right HF. We evaluated
the correlations and 95% conﬁdence intervals (CI) between invasive hemodynamic measurements and
serum high-sensitivity (hs) concentrations of cTnT.
Results: The serum cTnT concentration was equal to or more than the detection threshold (0.003 ng/ml)
in all patients. The serum cTnT concentration was equal to or more than the cut-off value of 0.014 ng/ml
in 46% of patients. By multiple variable analysis, left ventricular (LV) end-diastolic pressure (EDP;
adjusted coefﬁcient = 0.014; 95% CI 0.0003–0.029; P = 0.046) was positively correlated, while
hemoglobin (adjusted coefﬁcient = 0.079; 95% CI 0.140 to 0.018; P = 0.012), estimated glomerular
ﬁltration rate (adjusted coefﬁcient = 0.008; 95% CI 0.013 to 0.003; P = 0.004), and LV ejection
fraction (EF; adjusted coefﬁcient = 0.011; 95% CI 0.018 to 0.003; P = 0.004) were negatively
correlated with hs-cTnT concentrations.
Conclusion: In patients with stable chronic HF, LVEDP and LVEF correlate with the serum concentrations
of hs-cTnT, independently of other correlates of elevated plasma concentrations of hs-cTnT.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The serum concentration of cardiac troponin (cTn) is a widely
used biomarker of myocyte injury in patients with myocardial
ischemia, and a sensitive indicator for the early diagnosis and risk
stratiﬁcation of acute coronary syndrome [1]. cTn I and T are also
elevated in patients with congestive heart failure (HF) without
overt ischemia [2], representing a highly sensitive prognostic
marker of HF progression [3,4], though the mechanisms of
cTn elevation in this context are not completely understood.* Corresponding author at: Department of Cardiovascular Medicine, Hyogo
Prefectural Amagasaki Hospital, Higashidaimotsu 1-1-1, Amagasaki, Hyogo 660-
0828, Japan. Tel.: +81 6 6482 1521; fax: +81 6 6482 7430.
E-mail address: cardioys@kuhp.kyoto-u.ac.jp (Y. Sato).
http://dx.doi.org/10.1016/j.jjcc.2014.08.012
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsOne hypothesis is that cardiac decompensation itself causes
a continuous loss of cardiomyocytes and leak of cTn. In support
of this hypothesis, Horwich et al. [5] and Eggers et al. [6] found
an association between serum cTn concentrations and pulmo-
nary capillary wedge pressure (PCWP), suggesting that the
abnormal hemodynamics status contributes to the elevated
cTn in patients with HF. This hypothesis, however, has not been
conﬁrmed by comparisons between cTn concentrations and
direct invasive measurements of left ventricular (LV) end-
diastolic pressure (EDP), particularly in peripheral blood
sampling.
The primary objective of this study was to evaluate the
correlation between invasive measurements of left heart hemo-
dynamic function, and high sensitivity (hs) cTnT in patients with
stable chronic HF of various etiologies. reserved.
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Fig. 1. Distribution of cTnT in the overall study population. See text for further
explanations. Hs-cTnT, high sensitive cardiac troponin
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Study population
Data were retrospectively collected in 167 consecutive patients
presenting with chronic and stable HF, who underwent complete
right and left heart catheterization within one week from troponin
measurement. Coronary angiograms were concurrently performed
in all patients and patients with angiographically visible, high-
grade coronary stenosis were excluded. Patients presenting with
acute HF, acute coronary syndrome, coronary revascularization in
the last 6 months, mitral stenosis, clinically signiﬁcant right HF, or
patients undergoing hemodialysis were also excluded from the
study. This study complied with the principles outlined in the
Declaration of Helsinki. The authors had full access to and take
responsibility for the integrity of the data.
Hs-cTnT measurements
Serum hs-cTnT was measured from the blood sampling which
was collected from the vein of the arm, using the Elecsys 20101
assay (Roche Diagnostics, Tokyo, Japan). The detection threshold of
this assay is 0.003 ng/ml, while the 99th percentile of the upper
reference value for healthy subjects is 0.014 ng/ml.
Baseline characteristics of the study sample
The baseline characteristics and medication status were
obtained from patient interviews or reviews of their medical
records. Body mass index was calculated from the individual’s
body weight, expressed in kg, divided by the square of height,
expressed in meters. Ischemic heart disease was deﬁned as
a history of coronary revascularization, a signiﬁcant coronary
stenosis on angiography or positive result of stress tastings. Patients
with a fasting serum glucose  126 mg/dl, a non-fasting serum
glucose > 200 mg/dl, or treated with an anti-diabetic medication
were classiﬁed as diabetics. Hypertension was deﬁned as a
systolic blood pressure  140 mmHg, a diastolic blood pressur-
e  90 mmHg, or the use of an anti-hypertensive medication.
Hemodynamic measurements
Right heart catheterization was performed with a 7 or 5-French
Swan-Ganz catheter (Edwards Lifesciences, Tokyo, Japan) inserted
under local anesthesia from the femoral, brachial or jugular
approach. Mean right atrial pressure, mean pulmonary artery
pressure, and PCWP were measured at the end of expiration.
Cardiac output and cardiac index were measured by the
thermodilution method. Left ventriculograms were performed
with a 5 or 4-French pigtail catheter inserted into the left ventricle
from the femoral, brachial or radial approach. Mean aortic
pressure, LVEDP, LV ejection fraction (EF) and LV end-diastolic
volume were calculated from the measurements made during left
heart catheterization. Coronary angiograms were performed in all
patients.
Statistical analyses
The results are presented as means  standard deviation (SD) or
medians and interquartile range (IQR), as appropriate. The patient
population was divided into 2 groups based on the baseline hs-cTnT
concentration, using a cut-off value of 0.014 ng/ml, based on the 99th
percentile of the upper reference value for healthy subjects, as
mentioned earlier. Differences between the 2 groups were examined
with Fisher’s exact test or Wilcoxon rank-sum test, as appropriate.
Single and multiple variable, linear regression analyses wereperformed to examine the correlations between serum cTnT
concentrations and selected clinical, laboratory and hemodynamic
variables. We used the log-transformed hs-cTnT concentration
because of its positively skewed distribution. Variables emerging
with correlations at the P < 0.20 level in the single variable analysis
were entered in a stepwise regression model.
P value <0.05 was considered statistically signiﬁcant. The
statistical analyses were performed with the JMP1 software
version 9.0 (SAS Institute Inc., Cary, NC).
Results
Patient characteristics
We collected data from a total of 167 chronic heart failure
patients. The etiology of HF was an old myocardial infarction in
84 patients (50%), valvular heart disease in 28 (17%), hypertensive
heart disease in 26 (16%), dilated cardiomyopathy in 22 (13%) and
arrhythmia-induced in 7 (4%) patients. Troponin measurement to
the hemodynamic study was an average of 2.3 (2.0) days. The
serum hs-cTnT concentrations were equal to or more than the
detection threshold (0.003 ng/ml) in all patients, and equal to or more
than the selected cut-off value of 0.014 ng/ml in 77 patients (46%).
The median hs-cTnT concentration was 0.012 ng/ml (IQR 0.007–
0.022 ng/ml; Fig. 1).
Relationships between hs-cTnT and baseline patient characteristics
and laboratory data
The relationships between hs-cTnT and selected baseline
characteristics and laboratory measurements are shown in Table 1.
Hemodynamic measurements in patients with normal versus elevated
serum hs-cTnT concentrations
The hemodynamic measurements made in patients with versus
without elevation of serum cTnT concentrations are shown in
Table 2. Compared with patients whose hs-cTnT was 0.014 ng/ml,
patients whose hs-cTnT was above the cut-off concentration had
signiﬁcantly lower mean LVEF, and higher mean right atrial
pressure, pulmonary artery pressure, PCWP, and LVEDP. Mean
heart rate, cardiac index, LV end-diastolic volume index, and mean
aortic pressure were similar in both groups.
Outcomes of single and multiple variable regression analyses
By single variable analysis, age, female sex, mean pulmonary
artery pressure, PCWP, and LVEDP were positively correlated,
while serum hemoglobin, eGFR, and LVEF were negatively
Table 1
Comparisons of the baseline characteristics of patients with serum cTnT
concentrations 0.014 versus >0.014 ng/ml cut-off value.
cTnT
 0.014 ng/ml
cTnT
> 0.014 ng/ml
P
(n = 90) (n = 77)
Age (years) 69.3  11 72.0  11 0.080
Men 57 (63) 41 (53) 0.209
Body mass index (kg/m2) 23.3 [20.9–25.5] 23.7 [19.7–25.9] 0.560
Ischemic etiology 51 (57) 35 (45) 0.164
Hypertension 71 (79) 57 (74) 0.470
Diabetes 35 (39) 22 (29) 0.191
Hemoglobin (g/dl) 13.0  1.7 12.5  1.9 0.042
Estimated glomerular
ﬁltration rate
(ml/min/1.73 m2)
69.5  21 59.6  18 0.003
Hemoglobin A1c 5.83  0.81 5.89  1.14 0.670
Drug therapy
Renin-aldosterone-
angiotensin
antagonist
57 (63) 50 (65) 0.872
Beta-adrenergic blocker 70 (78) 53 (69) 0.219
Diuretic 32 (36) 48 (63) <0.001
Values are means  SD, numbers (%) of observations or medians [interquartile
range]. cTnT, cardiac troponin T.
Table 2
Hemodynamic measurements and serum cTnT concentrations.
cTnT
 0.014 ng/ml
cTnT
> 0.014 ng/ml
P
(n = 90) (n = 77)
Heart rate (bpm) 69.1  16 71.2  14 0.368
Central pressures (mmHg)
Mean right atrial 5.7  2.4 6.8  3.5 0.049
Mean pulmonary artery 18.7  5.3 22.3  8.0 0.003
Pulmonary capillary wedge 10.9  4.5 14.3  7.0 0.002
Left ventricular end-diastolic 13.5  6.1 16.9  8.4 0.010
Mean aortic 97  16 96  17 0.699
Cardiac index (l/min) 3.3  0.8 3.1  0.8 0.082
Left ventricular
End diastolic volume
index (ml/m2)
93  27 101  35 0.205
Ejection fraction (%) 50.1  12.8 44.9  15 0.048
Values are means  SD. cTnT, cardiac troponin T.
Table 3
Outcomes of single and multiple variable regression analyses.
Unadjusted 
Coefﬁcient SE 95% CI 
Age (years) 0.010 0.005 0.0003 
Sex (m = 1) 0.248 0.115 0.474 
Body mass index (kg/m2) 0.012 0.014 0.040 
Hemoglobin (g/dl) 0.102 0.031 0.015 
Estimated GFR (ml/min/1.72 m2) 0.010 0.003 0.015 
Glycated hemoglobin A1c (%) 0.047 0.059 0.069 
Heart rate (/min) 0.001 0.004 0.006 
Central pressures (mmHg)
Mean right atrial pressure 0.017 0.019 0.020 
Mean pulmonary artery pressure 0.017 0.008 0.0004 
Pulmonary capillary wedge pressure 0.022 0.009 0.003 
LV end-diastolic pressure 0.019 0.008 0.004 
Mean aortic pressure 0.003 0.003 0.009 
Cardiac index (l/min/m2) 0.108 0.071 0.248 
LV end-diastolic volume index (ml/m2) 0.003 0.002 0.0001 
LV ejection fraction (%) 0.009 0.004 0.017 
SE, standard error; CI, conﬁdence interval; GFR, glomerular ﬁltration rate; LV, left ve
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LVEDP was independently and positively correlated, while
hemoglobin, eGFR, and LVEF were independently and negatively
correlated with hs-cTnT. Because PCWP shows a good correlation
with LVEDP in general, they may be potential confounding
variables in multivariable analysis. However, in this study after
we excluded PCWP from a multivariable analysis, the result did not
change. In Fig. 2 the values of LVEDP, LVEF, hemoglobin and eGFR
are shown in 3 groups of different troponin levels (Group1:
Log TnT < 4.71, n = 56; Group2: 4.71  Log TnT < 4.017,
n = 57; Group3: 4.017  Log TnT, n = 54).
Discussion
Our study of patients presenting with stable HF found
signiﬁcant relationships between serum concentrations of hs-
cTnT and anemia, renal insufﬁciency, depressed LVEF and elevated
LVEDP.
Anemia and cTnT
About patients with heart failure, Ralli et al. had shown the
relationship between anemia and troponin concentration [7]. We
conﬁrmed the independent and linear correlation between
hemoglobin and serum hs-cTnT concentrations. The correlation
between hemoglobin and hs-cTnT was strong and independent
from other predictors of elevated hs-cTnT, such as renal
insufﬁciency. Anemia is common in presence of chronic inﬂam-
matory diseases, and some markers of inﬂammation are also
positively correlated with the serum concentrations of cTnT
[2,8]. Although in this study we did not investigate relationships
between anemia and inﬂammation, anemia concomitant with
inﬂammation may cause further elevation of cTnT in heart failure
than anemia alone.
Left ventricular function and cTnT
In this study LVEF was correlated with hs-cTnT concentrations
measured using the Elecsys 20101 assay (Roche Diagnostics,
Tokyo, Japan), however in our previous study LVEF was not
correlated with cTnI concentrations measured using rapid assay
PATHFAST (Mitsubishi Chemical, Tokyo, Japan) in patients
undergoing cardiac catheterization [9]. Although cTnT and cTnI
are both expressed in cardiomyocytes, it has been reported that theAdjusted
P Coefﬁcient SE 95% CI P
0.020 0.044
0.021 0.032
0.016 0.396
0.004 0.001 0.079 0.031 0.140 0.018 0.012
0.004 <0.001 0.008 0.003 0.013 0.003 0.004
0.163 0.421
0.008 0.806
0.054 0.361
0.033 0.045
0.040 0.021
0.034 0.011 0.014 0.007 0.0003 0.029 0.046
0.004 0.451
0.031 0.127
0.007 0.054
0.001 0.032 0.011 0.004 0.018 0.003 0.004
ntricular.
Fig. 2. The values of LVEDP, LVEF, hemoglobin and eGFR in 3 groups of different troponin levels (values are means  SE). See text for further explanations.
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such as male gender or renal failure, which may be due to epitopic
differences that are detected by individual assays and by the
degradation of troponin [10]. These differences in cTn may have
inﬂuenced our ﬁndings. The relationship between LVEF and
cTnT concentrations has been reported in other previous studies
[4,11–13]. Earlier studies in patients with chronic HF have shown
speciﬁc relationships between elevated cTn and cardiac load [5,6],
activation of the renin-angiotensin-aldosterone and sympathetic
nervous systems, and inﬂammation [2]. cTn is also a reliable
marker of LV remodeling [14–16]. In this study, LVEF was an
independent correlate of hs-cTnT, suggesting that its elevation
reﬂected a myocytic injury and LV remodeling secondary to
pathways that we did not identify.
Renal insufﬁciency increases the serum concentrations of cardiac
troponin
We observed a correlation between impaired renal function
and elevated hs-cTnT. Although the relationship between renal
function and cTn remains controversial, several previous studies
have found higher hs-cTnT concentrations in patients presenting
with chronic HF and chronic kidney disease than in patients
without renal insufﬁciency [17,18]. Earlier observations
revealed that fragments of cTnT are not properly excreted
by malfunctioning kidneys and remain in the plasma [19]. The
results of our study are concordant with these previous
observations.Left ventricular end-diastolic pressure and serum troponin
concentrations
The relationships between hemodynamic measurements and
cTn have been described in the studies by Horwich et al. [5] and
Eggers et al. [6]. Ours found a linear relationship between hs-cTnT
and LVEDP, which is the most reliable indicator of LV ﬁlling
pressure. Takashio et al. reported the differences between coronary
sinus (CS) and aortic root (Ao) cTnT levels correlate with LVEDP
[20]. However, because measurement of CS and Ao cTnT is difﬁcult
in real-world clinical practice, we investigated the relationships
between cTnT concentrations in peripheral blood sampling and
hemodynamic measurements. Our data support the hypothesis
that cardiac decompensation is associated with myocyte injury
and disease progression [21]. The association of elevated LVEDP
with elevated hs-cTnT remains unexplained. One hypothesis is
that high LV ﬁlling pressures cause myocyte injury by interfering
with endomyocardial perfusion [21]. Another experimentally
supported hypothesis is the release of cTn caused by myocytic
stretch [22].
Limitations of our study
To the best of our knowledge, this is the ﬁrst report showing a
correlation of LVEDP measured directly and LVEF calculated from
the measurements made during left heart catheterization with
hs-cTnT concentrations in peripheral blood sampling. Although we
know that cTnT released from falling myocardium correlate with
H. Shionimya et al. / Journal of Cardiology 65 (2015) 526–530530microvascular dysfunction in nonischemic HF patients [20], we do
not have data about it in this study. Furthermore, the results of our
study are limited by a relatively small patient sample and the
observational study design. Whether controlling LVEDP has an
impact on the serum concentrations of cTn and on prognosis
warrants further investigations.
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